An ongoing study (NCT02301130) currently investigates the combination of mogamulizumab (an anti-CCR4 mAb) with either MEDI4736 (anti-B7H1 mAb) or tremelimumab (anti-CTLA-4 mAb) to overcome the immunosuppression in pancreatic cancer. Here, CD274 is linked to familial pancreatic carcinoma.